Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4784235 | 0.88 | KMT2A (0.51) | MAPK8HDAC3MTORHDAC1HDAC2 | |
| SCHEMBL4784193 | 0.82 | DDR1 (0.51) | DDR1LMNAMAPK1NLRP1EPHX2 | |
| SCHEMBL4781301 | 0.82 | AURKA (0.54) | MAPK1 | |
| SCHEMBL4785037 | 0.81 | RAB9A (0.54) | LMNAROCK2ROCK1HDAC1 | |
| SCHEMBL4783322 | 0.80 | KMT2A (0.51) | MAPK1MAPK8HDAC1 | |
| SCHEMBL4783741 | 0.79 | KIT (0.52) | LMNAMAPK8ROCK2 | |
| SCHEMBL4783423 | 0.78 | KIT (0.51) | EPHX2MAPK8HDAC1 | |
| SCHEMBL4784112 | 0.76 | ALDH1A1 (0.54) | MAPK1EPHX2MAPK8ROCK2 | |
| SCHEMBL4780938 | 0.75 | MAPK1 (0.48) | MAPK1 | |
| SCHEMBL4784771 | 0.75 | LMNA (0.52) | LMNAMAPK1NLRP1EPHX2MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153810-A1 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-26 | — | — | US | claimed |
| WO-2008061109-A2 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | claimed |
| US-20080153810-A1 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-26 | — | — | US | disclosed |
| US-20080153810-A1 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-26 | — | — | US | disclosed |
| US-20080153810-A1 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-26 | — | — | US | disclosed |
| WO-2008061109-A2 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008061109-A2 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153810-A1 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | MCHR1, MCHR2, MC1R | DDR1 1750/4885LMNA 4549/4885MAPK1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.